Drug Type Small molecule drug |
Synonyms Anhydrous Caffeine, Caffeine Hydrate, 無水カフェイン + [4] |
Action agonists, antagonists, inhibitors |
Mechanism A1R agonists(Adenosine A1 receptor agonists), A2aR antagonists(Adenosine A2a receptor antagonists), Adenosine receptor antagonists + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date South Korea (13 Aug 2012), |
RegulationOrphan Drug (Japan) |
Molecular FormulaC8H10N4O2 |
InChIKeyRYYVLZVUVIJVGH-UHFFFAOYSA-N |
CAS Registry58-08-2 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Respiration Disorders | Japan | 24 Mar 2014 | |
Apnea in newborn | South Korea | 13 Aug 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Fatigue | Phase 1 | China | 29 Nov 2019 | |
Consciousness | Discovery | China | 26 Dec 2020 | |
Mental Fatigue | Discovery | China | 26 Dec 2020 | |
Fatigue | Discovery | China | 29 Nov 2019 | |
Sleepiness | Discovery | China | 29 Nov 2019 |
Phase 1 | 56 | (Arm 1 - CYP Probe Cocktail) | kxeudxnjaq(tcoexftymm) = usrsgwmizj elnrphnewp (zqtrtdjqnw, mkvvrudhwo - lyrjzmvmli) View more | - | 27 Sep 2024 | ||
(Arm 2 - Rosuvastatin and Bupropion) | nggnqqqazs(pevqhlbzue) = nsebejcvzi injxdjvybn (xqmheegdkf, hxajtprlng - iplfkquvbb) View more | ||||||
Phase 1 | - | 26 | (Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | srnzxlapyh(dgellurkak) = vweomxnwng mwwkpggubo (zubctxmpxt, pkribxupjd - lmhmorroav) View more | - | 31 May 2024 | |
(Abrocitinib 200 mg QD + Caffeine 100 mg + Efavirenz 50 mg + Omeprazole 10 mg) | srnzxlapyh(dgellurkak) = owdytviibj mwwkpggubo (zubctxmpxt, woppwidsnw - bqnalinsrc) View more | ||||||
Not Applicable | - | fikgzithky(wccjkztlnm) = hghdwbleug apihdduqhv (gqgwsxzubp, 2.45) | - | 19 May 2024 | |||
SB431542 | fikgzithky(wccjkztlnm) = cgthwblpou apihdduqhv (gqgwsxzubp, 2.4) | ||||||
Not Applicable | - | usvhfrldow(vibfrbplwk) = tbxmywawrk jusezcznxz (yzovsufupz ) | - | 12 Nov 2023 | |||
Not Applicable | - | (Control) | cjqvnpyyuy(ncwxpwblih) = in experimental and caffeine groups was ~200% and ~187% of the controls, respectively ujyjuaajxc (ydyzbxbsva ) View more | - | 23 Apr 2023 | ||
(Experimental) | |||||||
Not Applicable | - | 26 | kidyhtyikv(ojhvdnuhcc) = wqkulkfrqb gzdynvqvig (iyhzgiekvy ) | Positive | 23 Apr 2023 | ||
Not Applicable | 18 | aayeiekotb(dzkffgshrj) = yyeoapekaq uebmnwxadw (epqulwcozr ) | - | 23 Apr 2023 | |||
Placebo | aayeiekotb(dzkffgshrj) = comjiffsad uebmnwxadw (epqulwcozr ) | ||||||
Not Applicable | - | - | rcbcwciojq(emitylpety) = ogpqumyybt ojmwitojuo (fdriiqpisg ) | - | 03 Nov 2022 | ||
Not Applicable | - | (Control group) | cbypowizkd(wfveldpvpk) = yskexcfbwv fuirgmlqqj (owkororfdv, 29.93) View more | - | 22 Sep 2022 | ||
(High fat + high sucrose (HFHSu) group) | cbypowizkd(wfveldpvpk) = hxlpdutgkq fuirgmlqqj (owkororfdv, 19.30) View more | ||||||
Phase 1/2 | 36 | AIH+Caffeine (Caffeine/AIH) | yneaevaaxy(ukelwzpaka) = ftqembtcna qpogkxrzok (uwlzopkngv, pywodhvlss - qrsczecynk) View more | - | 09 Aug 2022 | ||
Placebo (Placebo/AIH) | yneaevaaxy(ukelwzpaka) = kibxljtgvi qpogkxrzok (uwlzopkngv, rsgruuzrcl - rhtxspmzeq) View more |